Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab in Advanced or Metastatic Chordoma
NCT05041127Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2022
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of KL-140 in chordoma, sponsored by University of Texas MD Anderson Cancer Center. Started May 2022; status: active, not recruiting.
02
Drugs
KL-140
03
Conditions
chordoma
Beyond the preview
Go deeper on NCT05041127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05041127.